The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It’s hardly likely to be gsk. Sir Tim has already worked there prior to Millenium. Sareum was set up as he could see molecules were just numbers in a long pipeline. Sareum is different, and he has stated, they are looking for partners who can run with it as far as it will go. Pronai have done well with Chk1 thus far.
Love peace and harmony.
The RNS said the trial stinks?
Not likely. The trial appears to be coming more bullet proof.
There’s some news to come regarding the journal “cell” and how they have tackled resistance in tyk2. Lupus. Selection of candidates. Hang together or hang separate, invest what you can afford.
Have a plan when to bail out, but it’s only my opinion, give it some time to mature.
Horse1 have you an opinion on the status quo?
Love peace and harmony.
Of all the great research this board brings. Number 1 character strength required is patience. It appears not to be” a does it work?” RNS or RNS’s that are coming. Invest what you can at an unbelievable price. In the words of Brian cox “ things can only get better”
Love peace and harmony
Like what’s already been said. Candidate selection on tyk2, jak2 causes bone brittleness and is the death knell for many previous trials. No derogatory news on Lupus. There’s also the cell interferon adjustment that they mentioned in a RNS that we have news coming. Patent news possibly forthwith.
Our/ Pronai Chk1 has a quirky side arm to help with dosing levels . Nearing news on phase 2 cohort numbers reached.
Another jontangle cockwomble quote, informed research from an informed board.
Aurora possibly.
My investment is what I can afford to hold without needing it for any other reason.
for?
Tyk2 selection, with licences for both by the end of the year. 5-10% upfront payment. With news on lupus.
A buyout may be dependent on the acquirer reducing risk and thus reducing the price, our nice joker is the Chk1.
If we’re honest, we’d like to see a buyout for £375-400 million. It may be possible.
With aurora hopefully the 10/10 syndrome has followed on into limited preclinical, Sir Tim did mention that CRUK has had one that’s been parked up for over a year, with no interest to license.
What’s your thoughts?
Love peace and harmony.
iPedro, absolutely. Here they have the dice loaded on their side. Quirky side arm to deal with efficacy. Many indications, and evidence of a best in class molecule. Scanning of cohorts prior to selection.It wouldn’t surprise to hear of cohorts becoming cancer free. Tyk2 has evidently shown to be better than a marketed drug. A number of variants showed superior results. So Sir Tim and John have now taken this to the umpteenth degree, academia, and the like.To find the best molecule to move forward. Buy what you can afford. We are cheaper now than when the nhs trials were announced for Chk1. Come on Sareum!!!
Deal is imminent. Afham3 earlier was pretty spot on imo. 2 tyk2 molecules. Otherwise srra have eyes on taking it to market themselves. (Chk1) Big buying opportunity this next month. Good news incoming. This has been a well informed board. Thankfully not full of tosh. Love peace and harmony.
Absolutely Ahfam3. There is evidence that Sareum have already received payments from CHK1 in their final results, with once the phase 2 has recruited the cohorts and first dosed them, another one to come. Albeit 27.5%. Sareum have evidence that tyk2 is outperforming a marketed molecule in pre clinical studies. We�ve got formulation issues with a molecule that cured cancer in 10/10 mice, and fully granted, it may not be resolved. Perhaps some nano particle technology to deliver our molecule to the heart of the cancer could help. Oral or IV. How someone recommending the post of an impatient investor in a business model that is doing what it says on the tin, and producing best in class molecules, patented via the SKIL platform, could show any new investor to research where you invest, before investing. I�m clearly biased and feel it�s all going to plan. Love peace and harmony.
We are approaching the end of the development of our candidates. This is the time when the little things that happen matter. �Middle of the year� said Sir Tim, that could be from now until August. Or longer. It can be a matter of elimination regarding using nano particles to whom we have asked for assistance regarding aurora. We know it�s not long after selection that a license is delivered and remember this is their business plan. My apologies for ramping about it last year and getting it clearly wrong. Now we have heard it from the horses mouth, there can only be one way this sp is going to go by end of the year. Can someone link any bad data on our tyk2? Have your stock ready that you want to sell when the license or buyout comes. There isnt many mundane RNS left. Love peace and harmony.
The preclinical development candidate to which Sareum regains rights has showed particular promise against a range of haematological cancer models including AML and Acute Lymphoblastic Leukaemia (ALL) with good tolerance of the candidate drug at the predicted therapeutic dose, and no significant side effects being seen. From the RNS today , the fact no significant side effects being seen is very good. However a couple of paragraphs down from that they are telling us that mtd hasn�t been tested due to the formulation aspect. We knew this already. However it�s an issue that must be resolved if it�s going to go on and go into humans. They�ve been proactive. As an investor it�s about being patient. My own thoughts are that a couple of months after tyk2 selection a deal will be announced. Of course I have a dream that Sareum will be bought out. And of course I know jack. My average is now the same as the mid price, so I�m neither at a loss or profit. It was more of a formality RNS today. Sareum is on the square. Here�s hoping the Renault Clio lasts out till the licence RNS :) Love peace and harmony.